Form 4: OptiNose Director Catherine E. Owen Acquires 75,000 Stock Options

Director Catherine E. Owen acquired 75,000 stock options in OptiNose, Inc. on June 6, 2024.

Summary

• Catherine E. Owen, a director of OptiNose, Inc., reported a transaction involving the acquisition of 75,000 stock options on June 6, 2024.
• The options have an exercise price of $1.04.
• The options vest and become exercisable on the earlier of June 6, 2025, or the Issuer's 2025 annual meeting of stockholders, contingent upon continued service with the Issuer.
• The expiration date for these options is June 6, 2034.
• Following the transaction, Owen directly owns 75,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director is generally a good sign, but it's a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continued service with the Issuer, suggesting an incentive for the director to remain with the company.

Industry Context

This is a standard practice for incentivizing company directors and aligning their interests with those of the shareholders. Stock options are a common form of executive compensation in the pharmaceutical industry.

Stakeholder Impact

• The acquisition of stock options by a director aligns their interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates